Health News Releases

  • Today July 1
July 17, 2024 14:50
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
SOTIO Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sotio.com%2F&esheet=54094919&newsitemid=20240716652691&lan=en-US&anchor=SOTIO+Biotech&index=1&md5=279e5245d8e335ff5
July 12, 2024 15:20
ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM
ILJIN SNT Co., Ltd. (“ILJIN”), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued an open letter to fellow shareholders. The full text
July 12, 2024 11:30
Parse Biosciences Launches Certified Service Provider Program
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54093141&newsitemid=20240711445815&lan=en-US&anchor=Parse+Biosciences&index=1&md
July 11, 2024 15:50
Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)
Viromed Medical AG (ISIN: DE000A3MQR65; “Viromed”) is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP). The study, under the sc
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
July 11, 2024 11:41
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfamprid
Brandnew Lab launches three ‘Nuvoen’ ampoule series for clinics
July 10, 2024 15:56
Brandnew Lab launches three ‘Nuvoen’ ampoule series for clinics
Brandnew Lab announced that it has launched three ampoule products - Boost, Lipo, and PLLA - under its clinic solution brand ‘Nuvoen’, which has the slogan ‘bring new vitality to the skin’, on July 10
July 10, 2024 15:25
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=54090621&newsitemid=20240709821670&lan=en-US&anchor=MMI&index=1&md5=df42141cdf355f8be68a32aeb0578189)
DRX-Evolution Plus (Photo: Business Wire)
July 04, 2024 14:10
Enhancing Technologist Experience and Patient Workflow, Carestream Reveals New Enhancements to CARESTREAM DRX-Evolution Plus System and ImageView Software
Carestream Health announced today the addition of new enhancements to its ImageView Software and DRX-Evolution Plus System, marking the latest improvements to its line of innovative, industry-leading
July 04, 2024 10:50
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/da
July 01, 2024 16:35
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mes
Left to right: Mitchell Rubin, Medisca CFO | Assemblyman Billy Jones | Stephane Nizri, Medisca Head
June 28, 2024 14:10
Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri
June 28, 2024 11:30
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capab
June 27, 2024 14:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary M
ENCell presented promising results from their First-in-Human Phase 1 clinical trial of the novel me
June 27, 2024 13:58
ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference
ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell
Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)
June 27, 2024 13:20
PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science
PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI bas
June 26, 2024 14:45
Kenvue Releases Inaugural Healthy Lives Mission Report
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Co
June 26, 2024 12:00
RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, F
June 25, 2024 09:43
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unres
June 25, 2024 09:26
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54085563&newsitemid=20240624910432&lan=en-US&anchor=TSE%3A4
June 23, 2024 16:00
Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri (https://www.esri.com/en-us/about/ab
June 23, 2024 13:54
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, to
June 23, 2024 12:47
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment
QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This locat
June 21, 2024 13:40
QPS Announces New Global Clinical Research Operations Leadership
QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medi
June 21, 2024 11:25
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to ac
June 20, 2024 14:15
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&newsitemid=20240618911375&lan=en-US&anchor=%28TSE%3A4502%2FNY
25 per page50 per page75 per page100 per page